Evidence map›Paper›PMID 29968947›Full record

ArticleTransplant infectious disease : an official journal of the Transplantation Society2018

Recurrent membranous nephropathy and acute cellular rejection in a patient treated with direct anti-HCV therapy (ledipasvir/sofosbuvir).

Naoka Murakami, Yanli Ding, David J Cohen, Anil K Chandraker, Helmut G Rennke

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Transplant infectious disease : an official journal of the Transplantation Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Naoka MurakamiSchuster Transplant Research Center, Brigham and Women's Hospital, Boston, Massachusetts.ORCID http://orcid.org/0000-0001-8168-5811
Yanli DingDepartment of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
David J CohenWest Palm Beach VA Medical Canter, West Palm Beach, Florida.
Anil K ChandrakerSchuster Transplant Research Center, Brigham and Women's Hospital, Boston, Massachusetts.
Helmut G RennkeDepartment of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
Brigham and Women's Hospital · USWest Palm Beach VA Medical Center · US

Funding

TRAINING PROGRAM IN ACADEMIC NEPHROLOGYT32DK007527 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI BONVENTRE, JOSEPH VINCENT · 1986 to 2021
$8.8M
NIDDK NIH HHS T32 DK007527
6 · The paper itself

Abstract

Direct-acting antiviral agents (DAAs) are very effective therapy for chronic hepatitis C infection, and have revolutionized the treatment of hepatitis C in kidney allograft recipients. Although well tolerated in general, rare renal complications have been reported. We describe a case of recurrent membranous nephropathy and acute cellular rejection in a kidney allograft recipient after DAA (ledipasvir/sofosbuvir) therapy, whose allograft function had been stable for more than 30 years. The patient was presented with nephrotic range proteinuria with stable creatinine. The kidney allograft biopsy revealed recurrent membranous nephropathy with fine granular deposits of IgG1/IgG4 codominance and positive phospholipase A2 receptor (PLA2R) staining. The patient was treated with pulse steroid and rituximab, leading to a decrease in proteinuria. As DAAs are more frequently used, physicians should be aware of immune-related renal complications.

Indexed as

AgedAllograftsAntiviral AgentsBenzimidazolesBiopsyFluorenesGlomerulonephritis, MembranousGraft RejectionHepacivirusHepatitis C, ChronicHumansImmunosuppression TherapyKidneyMaleRecurrenceSofosbuvirAntiviral AgentsBenzimidazolesFluorenesledipasvir, sofosbuvir drug combinationSofosbuvirUridine Monophosphatedirect-acting antiviralhepatitis Ckidney transplantationrecurrent membranous nephropathy

Identifiers

PMID29968947
PMCPMC6176715
OpenAlexW2811064568

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.